Onani Zimba
Centers for Disease Control and Prevention, Botswana
Tsaone Tamuhla
Botswana University of Pennsylvania, Botswana
Joyce Basotl
Centers for Disease Control and Prevention, Botswana
Gaoraelwe Letsibogo
National Tuberculosis Reference Laboratory, Ministry of Health and Wellness, Botswana
Sherri Pals
Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Unami Mathebula
Centers for Disease Control and Prevention, Botswana
Anikie Mathom
Centers for Disease Control and Prevention, Botswana
Christopher Serumola
Centers for Disease Control and Prevention, Botswana,
Kitso Ramogale
Botswana University of Pennsylvania, Botswana
Rosanna Boyd
Centers for Disease Control and Prevention, Botswana;5Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta Georgia, United States of America
Tiffany Tran
Centers for Disease Control and Prevention
Alyssa Finlay
Centers for Disease Control and Prevention, Botswana;Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta Georgia, United States of America
Andrew Auld
4Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Heather Alexande
Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Violet Chihota
The Aurum Institute, Johannesburg, South Africa;School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, 8Department of Family Medicine and Public Health, Faculty of Medicine, University of Botswana, Botswana
Tefera Agizew
School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa;Department of Family Medicine and Public Health, Faculty of Medicine, University of Botswana, Botswana
Abstract
Introduction: the World Health Organization endorsed (2010) the use of Xpert MTB/RIF and countries are shifting from smear microscopy (smear)-
based to Xpert MTB/RIF-based tuberculosis (TB) diagnostic algorithms. As with smear, sputum quality may predict the likelihood of obtaining a
bacteriologically-confirmed TB when using Xpert MTB/RIF. Methods: from 08/12-11/2014, all people living with HIV were recruited at 22 clinics. For
patients screened positive using the four TB symptoms their sputa were tested by Xpert MTB/RIF and smear. Laboratorians assessed and recorded
sputum appearance and volume. The yield of bacteriologically-positive sputum evaluated using Xpert MTB/RIF and smear, likelihood-ratios were
calculated. Results: among 6,041 patients enrolled 2,296 were presumptive TB, 1,305 (56.8%) had > 1 sputa collected and 644/1,305 (49.3%)
had both Xpert MTB/RIF and smear results. Since >1 sputa collected from 644 patients 954 sputa were tested by Xpert MTB/RIF and smear.
Bacteriologically-positive sputum was two-fold higher with Xpert MTB/RIF 11.4% versus smear 5.3%, p < 0.001. Sputum appearance and quantity
were not predictive of bacteriologically-positive results, except volume of 2ml to < 3ml, tested by Xpert MTB/RIF LR+= 1.26 (95% CI, 1.05–1.50).
Conclusion: Xpert MTB/RIF test yield to bacteriologically-positive sputum was superior to smear. Sputum quality and quantity, however, were not
consistently predictive of bacteriologically-positive results by Xpert MTB/RIF or smear.